{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}],"title":"WBC GR1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}],"title":"WBC GR2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"}]}],"title":"WBC GR3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}],"title":"WBC GR4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}],"title":"ANC GR1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"ANC GR2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}],"title":"ANC GR3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"13"}]}],"title":"ANC GR4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}]}],"title":"Platelet GR1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}],"title":"Platelet GR2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"}]}],"title":"Platelet GR3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"}]}],"title":"Platelet GR4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}],"title":"Hemoglobin GR1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}],"title":"Hemoglobin GR2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}],"title":"Hemoglobin GR3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Hemoglobin GR4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. White Blood Cell (WBC):GR1=\\<LLN-3.0\\*10\\^9/L; GR2=\\<3.0-2.0\\*10\\^9/L; GR3=\\<2.0-1.0\\*10\\^9/L; GR4=\\<1.0\\*10\\^9/L. Absolute Neutrophil Count (ANC): GR1=\\<LLN-1.5\\*10\\^9 /L; GR2=\\<1.5-1.0\\*10\\^9/L; GR3=\\<1.0-0.5\\*10\\^9/L; GR4=\\<0.5\\*10\\^9/L. Hemoglobin: GR1=\\<LLN-10.0g/dL; GR2=\\<10.0-8.0g/dL; GR3=\\<8.0-6.5g/dL; GR4=\\<6.5g/dL. Platelets: GR1=\\<LLN-75.0\\*10\\^9/L; GR2=\\<75.0-50.0\\*10\\^9/L; GR3=\\<50.0-25.0\\*10\\^9/L; GR4=\\<25.0\\*10\\^9/L. LLN=lower limit of normal.","groups":[{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Starting Dose Level of 60 mg/m\\^2; Escalated/Dose Level 2 of 80 mg/m\\^2. Once daily (QD), as long as clinical benefit was maintained.","id":"OG000","title":"Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose"},{"description":"Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Starting Dose Level of 60 mg/m\\^2; Escalated/Dose level 2 of 80 mg/m\\^2. QD, as long as clinical benefit was maintained.","id":"OG001","title":"Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Starting Dose Level of 60 mg/m\\^2; Escalated/Dose level 2 of 80 mg/m\\^2, Escalated/Dose level 3 of 100 mg/m\\^2, and Escalated/Dose level 4 of 120 mg/m\\^2. QD, as long as clinical benefit was maintained.","id":"OG002","title":"Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose"}],"paramType":"NUMBER","populationDescription":"All treated participants: Participants who received at least one dose of study therapy.","reportingStatus":"POSTED","timeFrame":"At baseline (within 1 week before initiation of study therapy)","title":"Number of Participants With Hematologic Toxicity at Baseline by NCI CTCAE Version 3.0","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"participants"}